Clinical outcomes and prognostic value of MRD in patients with NPM1-mutated AML

We summarize the clinical outcomes of patients with R/R AML by NPM1-mutational status following different salvage...

ASAP: Conditioning vs induction + allo-HSCT in R/R AML

We summarize key findings from the ASAP trial comparing sequential conditioning prior to allo-HSCT vs salvage chemotherapy followed by allo-HSCT...

ASH 2022 roundup: IDH inhibitors

Here, we summarize safety and efficacy data for enasidenib and ivosidenib and the association between IDH mutations in patients with AML and relapse rates after...

Addition of gemtuzumab ozogamicin to induction chemotherapy

We summarize several presentations from ASH 2022 on the impact of gemtuzumab ozogamicin plus chemotherapy and fractionated versus single...

Impact of MRD status on outcomes in patients with AML treated with different treatment regimens

We summarize a retrospective study assessing the impact of MRD on outcomes in patients with AML treated...

Quizartinib granted approval in Japan for the treatment of patients with newly diagnosed AML with FLT3-ITD mutations

On May 25, 2023, quizartinib, an oral, highly potent, and selective type II FLT3...

Ivosidenib granted approval by the European Commission for the treatment of adult patients with IDH1-mutated AML

On May 10, 2023, ivosidenib, a small molecular isocitrate dehydrogenase-1 (IDH1)...

Clinical outcomes and prognostic value of MRD in patients with NPM1-mutated AML

We summarize the clinical outcomes of patients with R/R AML by NPM1-mutational status following different salvage...

Optimizing induction therapy in older patients with AML undergoing allo-HSCT

In this article, we summarize the impact of the type of induction therapy on outcomes in older patients with AML undergoing...

Impact of MRD status on outcomes in patients with AML treated with different treatment regimens

We summarize a retrospective study assessing the impact of MRD on outcomes in patients with AML treated...

Impact of allo-HSCT and Fried’s frailty phenotype in older patients with AML

We summarize a study assessing the benefits of allo-HSCT in older patients with AML and a study evaluating the impact of...

“How I treat” case studies incorporating updated classification systems

Here, we summarize key points from a “How I treat” article by Chaer et al., published in Blood, discussing the treatment of...

Decitabine shows comparable OS to standard induction chemotherapy and better safety in patients with AML

Lübbert et al. investigated the efficacy and safety of a 10-day decitabine regimen compared to...

Quizartinib, decitabine, and venetoclax combination therapy in patients with AML and prior exposure to FLT3 inhibitors

During the European Hematology Association (EHA) 2022 Congress, the triplet...

Does 10-day decitabine improve post-transplant outcomes in older patients compared with 3+7 chemo?

Ossenkoppele begins by introducing the study presented at the congress, outlining the study design...

The QuANTUM-First trial

During the EHA 2022 Congress, the AML Hub was pleased to speak with Hee-Je Kim, The Catholic University of Korea, Seoul, KR, about the initial findings from the QuANTUM-First...